RNAi‐mediated downregulation of uPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells
Authors:
Open Access
- 4 August 2010
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 127 (7) , 1507-1516
Abstract
Overexpression of urokinase plasminogen activator receptor (uPAR) or HER2 (erbB‐2) in breast cancer is associated with a poor prognosis. We previously reported that gene amplification and overexpression of HER2 and uPAR occur in 70% of HER2‐amplified tumor cells from blood or tissue of patients with breast cancer. In this study, we first examined whether depletion of HER2 and uPAR synergized in suppression of the growth of breast cancer cells that overexpress both HER2 and uPAR (SKBR3 and ZR 751). The results showed that depletion of either HER2 or uPAR by RNA interference suppressed cell growth and induced cell apoptosis, but that these effects were significantly enhanced in cells depleted of both HER2 and uPAR. Mechanistic analysis demonstrated that silencing of HER2 and uPAR caused suppression of MAPK signal pathways, resulting in decrease of ERK activity and prompting a high p38/ERK activity ratio. The level of the phosphorylated form of ERK was decreased in cells depleted of HER2, uPAR or both, and the effect in cells depleted of both is the most evident. Moreover, downregulation of uPAR synergized with trastuzumab to suppress the growth and induce apoptosis of SKBR3 and ZR 751 cells. uPAR RNAi significantly enhanced the effect of trastuzumab on inhibition of MAPK signal pathways. In conclusion, targeting HER2 and uPAR has a synergistic inhibitory effect on breast cancer cells. Our results provide evidence that simultaneous downregulation of HER2 and uPAR may offer an effective tool for breast cancer therapy.Keywords
This publication has 39 references indexed in Scilit:
- The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 InhibitorsCancer Research, 2009
- Models, mechanisms and clinical evidence for cancer dormancyNature Reviews Cancer, 2007
- Retracted: RNAi‐mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease‐9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growthInternational Journal of Cancer, 2007
- uPAR and HER-2 gene status in individual breast cancer cells from blood and tissuesProceedings of the National Academy of Sciences, 2006
- Urokinase receptor primes cells to proliferate in response to epidermal growth factorOncogene, 2006
- Stable RNA interference of ErbB-2 gene synergistic with epirubicin suppresses breast cancer growth in vitro and in vivoBiochemical and Biophysical Research Communications, 2006
- Upregulation and activation of PKCα by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKCα and Src inhibitorsOncogene, 2006
- RNA Interference-directed Knockdown of Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor Inhibits Prostate Cancer Cell Invasion, Survival, and Tumorigenicity in VivoJournal of Biological Chemistry, 2005
- Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1Thrombosis and Haemostasis, 2005
- Real‐time quantitative PCR determination of urokinase‐type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patientsInternational Journal of Cancer, 2004